Key facts
- It has raised $820K; the latest was Angel (individual) ($820K) in Oct 2025.
- Notable investors include J. Bradley Hilton, Martin Lewis.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Nok Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nok Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nok Therapeutics
Operator of a clinical-stage biotechnology company designed to develop autologous, non-engineered natural killer cell therapies to restore immune defense in high-relapse cancers. The company offers cell therapies for cancer treatment to restore immune defense without lymphodepletion, helping cancer patients to cure cancer by providing a safer and effective alternative to traditional cell therapies.
- Sector
- Healthcare
- HQ
- Ormond Beach, FL, United States
- Founded
- 2024
- Website
- noktx.com/
- Ownership
- Privately Held (backing)
Nok Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nok Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nok Therapeutics in its N-PORT filings yet. We sweep new filings monthly.